Post-cycle therapy (PCT) after SARMs: the complete guide to testosterone recovery

Marketing claims often suggest that SARMs do not suppress natural testosterone production and thus require no post-cycle recovery. This is medically incorrect. While selective, SARMs still bind to androgen receptors, signaling the hypothalamus to downregulate LH and FSH production, which suppresses the HPTA axis.

Why SARMs Require Post-Cycle Therapy

Androgen receptors in the brain respond to SARMs, leading to a negative feedback loop. Compounds like Ligandrol (LGD-4033) or RAD-140 cause pronounced shutdown, making active intervention crucial to restart natural hormone secretion and prevent lethargy and muscle loss.

Recovery Protocols and Compound Selection

A Post-Cycle Therapy (PCT) protocol is intended to restore endogenous hormone production and prevent symptoms like lethargy, muscle loss, and mood disturbances. Standard recovery plans utilize Selective Estrogen Receptor Modulators (SERMs) such as Clomiphene (Clomid) or Tamoxifen (Nolvadex). Clomiphene is effective at stimulating gonadotropins, whereas Tamoxifen is often chosen for its milder side-effect profile and positive impact on lipids.

Clinical Indicators for PCT Completion

A recovery protocol should not be ended blindly. True restoration of the HPTA axis must be verified through post-PCT blood work measuring free and total testosterone, LH, FSH, and liver enzymes to confirm a return to physiological baselines.